Publications by authors named "Takashi Seto"

Claim this Profile
R
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated -Mutated Metastatic NSCLC.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
Akito Hata, Taira Ninomaru, Hideaki Okada, Yoshihito Kogure, Masahide Oki, Takashi Seto

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic -mutated NSCLC.
Kazumi Nishino, Takashi Seto, Makoto Nishio, Kazuto Nishio, Kazuo Kasahara

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated -Mutated Metastatic NSCLC: RELAY Japanese Subset.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio

JTO Clin Res Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance.
Takashi Seto, Sayuri Nakane, Lyu Ji, Yuya Ueda, Hiroshi Sugano

Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix

J Thorac Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, Noemi Reguart, Pierre-Jean Souquet, Takashi Seto

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Kaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa, Hidehito Horinouchi, Masahiro Morise, Takashi Seto

Int J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.
Benjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, Michael J Boyer, Suresh S Ramalingam, Takashi Seto

JTO Clin Res Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Naoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, Miyako Satouchi, Takashi Seto

Invest New Drugs· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, Kiyotaka Yoh, Haruhiro Saito, Takashi Seto

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Ayako Matsuda, Kazue Yamaoka, Hideo Kunitoh, Takashi Seto, Masahiro Tsuboi

Qual Life Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto

Cancer Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with -activating mutations (RELAY phase 3 randomized study).
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, Takashi Seto, Carla Visseren-Grul

Transl Lung Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Yuka Oku, Gouji Toyokawa, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Takashi Seto

Cancer Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced non-small-cell lung cancer.
Makoto Nishio, Shinji Atagi, Koichi Goto, Yukio Hosomi, Takashi Seto

Transl Lung Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Takashi Seto

Int J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications.
Gouji Toyokawa, Francesca Bersani, Paolo Bironzo, Francesca Picca, Fabrizio Tabbò, Takashi Seto

Crit Rev Oncol Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.
Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Takashi Seto

Front Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRUST-II: a global phase II study of taletrectinib in -positive non-small-cell lung cancer and other solid tumors.
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, Chang-Min Choi, Nong Yang, Takashi Seto

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Takashi Seto

Int J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Takashi Seto

Int J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With -Positive Advanced NSCLC.
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, Jianying Zhou, Takashi Seto

JTO Clin Res Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Yoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, Yoichiro Hamamoto, Akiko Kada, Takashi Seto

Lancet Healthy Longev· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis